Anti-Inflammatory Effects of Thymoquinone in Atherosclerosis: A Mini Review

Atherosclerosis poses serious health problems and increases the risk of various cardiovascular diseases, including myocardial infarction, heart failure, ischemic stroke, and peripheral arterial disease. Atherosclerosis patients require long-term medications to prevent complications, some of which ar...

Full description

Bibliographic Details
Main Authors: Alias, A (Author), Choy, KW (Author), Leong, XF (Author)
Format: Article
Language:English
Published: 2021
Subjects:
RAT
Online Access:View Fulltext in Publisher
LEADER 02212nam a2200325Ia 4500
001 10.3389-fphar.2021.758929
008 220223s2021 CNT 000 0 und d
245 1 0 |a Anti-Inflammatory Effects of Thymoquinone in Atherosclerosis: A Mini Review 
260 0 |c 2021 
856 |z View Fulltext in Publisher  |u https://doi.org/10.3389/fphar.2021.758929 
520 3 |a Atherosclerosis poses serious health problems and increases the risk of various cardiovascular diseases, including myocardial infarction, heart failure, ischemic stroke, and peripheral arterial disease. Atherosclerosis patients require long-term medications to prevent complications, some of which are costly and may result in unwanted adverse reactions. Natural products have emerged as potential sources of bioactive compounds that provide health benefits in cardiovascular diseases. Increased inflammation and vascular remodeling have been associated with atherosclerosis pathogenesis. The molecules involved in signaling pathways are considered valuable targets for new treatment approaches. Therefore, this review aimed to summarize the available evidence of the anti-inflammatory effects of thymoquinone, the major active compound isolated from Nigella sativa L., via inflammatory signaling pathways in atherosclerosis. Specifically, nuclear factor-kappa B and mitogen-activated protein kinase signaling pathways were considered. Furthermore, the potential toxic effects elicited by thymoquinone were addressed. These findings suggest a potential role of thymoquinone in managing atherosclerosis, and further studies are required to ascertain its effectiveness and safety profile. 
650 0 4 |a atherosclerosis 
650 0 4 |a CELL-PROLIFERATION 
650 0 4 |a CYTOKINE 
650 0 4 |a EXPRESSION 
650 0 4 |a INFLAMMASOME 
650 0 4 |a inflammation 
650 0 4 |a LOW-DENSITY-LIPOPROTEIN 
650 0 4 |a MIGRATION 
650 0 4 |a mitogen-activated protein kinase 
650 0 4 |a nuclear factor-kappa B 
650 0 4 |a PATHWAY 
650 0 4 |a RAT 
650 0 4 |a SEEDS 
650 0 4 |a thymoquinone 
650 0 4 |a TOXICITY 
700 1 0 |a Alias, A  |e author 
700 1 0 |a Choy, KW  |e author 
700 1 0 |a Leong, XF  |e author 
773 |t FRONTIERS IN PHARMACOLOGY